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Abstract
Background: Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors
I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells.
Methods: Patients (pts) with Her2/neu (1+/SISH positive, 2+ and 3+) expressing tumors progressing after standard
therapy were treated to investigate safety, tolerability and preliminary efficacy. In this study, ertu was applied i.v. in
2 cycles following a predefined dose escalating scheme. Each cycle consisted of five ascending doses (10–500 μg)
applied weekly within 28 days with a 21 day treatment-free interval. If 2 pts experienced a dose limiting toxicity (DLT)
at a given dose level, the maximum tolerated dose (MTD) had been exceeded.
Results: Fourteen heavily pretreated pts (e.g. breast, rectal, gastric cancer) were enrolled in the four main cohorts.
Three (21 %) pts had to be replaced. Two serious adverse events (SAE) with possible relation to the investigational drug
were seen, both fully reversible. A DLT was not detected. Consequently, the MTD could not be determined. All adverse
events (AE) were transient and completely reversible. Most frequent AEs were fatigue (14/14), pain (13/14), cephalgia
(12/14), chills (11/14), nausea (8/14), fever (7/14), emesis (7/14) and diarrhea (5/14). Single doses up to 300 μg were well
tolerated (total dose up to 800 μg per cycle). We observed one partial remission and two disease stabilizations after
first treatment cycle.
Conclusions: Single doses up to 300 μg could be safely administered in an escalating dose scheme. Immunological
responses and clinical activity warrant further evaluation in patients with Her2 over expressing tumors.
Trial registration: EudraCT number: 2011-003201-14; ClinicalTrials.gov identifier: NCT01569412
Keywords: Ertumaxomab, Her2/neu, Advanced cancer, Dose limiting toxicity, Dose escalation, Maximum tolerated dose
Background
The most known member of the epidermal growth re-
ceptor family, Her2/neu, is frequently found to be over-
expressed in various types of cancers like breast cancer,
gastric cancer, lung cancer and ovarian cancer. An in-
creased Her2/neu expression results in a more aggres-
sive tumor behavior. Thus, many studies have indicated
that Her2/neu overexpression is associated with a poor
prognosis and with a significantly shorter overall survival
rate and time to relapse for patients with Her2/neu ex-
pressing tumors [1–3].
The Her2/neu (c-ErbB-2) proto-oncogene encodes an
185kD trans-membrane glycoprotein that takes action as
a tyrosine kinase receptor [3]. As a tyrosine kinase re-
ceptor, Her2/neu participates in an interactive network
of receptor interactions resulting in complex signaling
pathways to control and regulate cell growth, migration,
differentiation and death [3–5].
An overexpression of Her2/neu, often caused by amplifi-
cation of the c-ErbB-2 gene, leads to enhanced tyrosine
phosphorylation activity and therefore to increased cell pro-
liferation and metastatic transformation in tumors [5, 6].
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Thus, the Her2/neu receptor serves as an effective target
for antineoplastic agents [6].
Bispecific antibodies are a new and promising ap-
proach for immunologic treatment of cancer cells.
Therefore, a simultaneous and powerful activation of ef-
fector cells such as T cells, NK cells and dendritic cells is
preferable. However, the bispecific antibodies generated
so far normally activate only a single class of effector
cells resulting in an insufficient immunologic attack
against tumor cells [7]. Triomab® antibodies represent a
new class of bispecific, hybrid-hybridoma derived anti-
bodies configured of two potent subclasses of mouse
IgG2a and a rat IgG2b chain. As a welcoming result of
this structure, triomab® antibodies possess three different
binding sides: a tumor-associated antigen (TAA)-specific
binding arm, a second arm specific for CD3 expressed
on T cells, and a chimeric mouse IgG2a x rat IgG2b Fc
region that recognizes Fcγ receptors type I, IIa and III
present on accessory cells such as macrophages, den-
dritic cells or NK cells [8–10].
Here, we report data on a new immunotherapeutic
agent, ertumaxomab (ATC code L01XC). Ertumaxomab
is a bispecific, trifunctional antibody that binds to Her2/
neu as its tumor-associated antigen, to CD3 and to Fcγ
forming a tri-cell complex between tumor cell, T cell
and accessory cells (Fig. 1). As a result, various immuno-
logic mechanisms are induced to initiate a polyclonal
humoral and cellular immune response to destroy Her2/
neu expressing tumor cells:
a) Mediation of T cell activation by CD3 binding re-
sults in tumor cell killing by e.g. cytokine release and re-
lease of lytic enzymes such as perforins [7, 11]. b) T cells
receive a second activating signal by release of stimulat-
ing cytokines (e.g. IL-2) and a crosstalk between costi-
mulatory molecules now expressed on T cells and
accessory cells [7, 12]. c) Necrotic or apoptotic tumor
particles are phagocytized by Fcγ positive cells such as
macrophages resulting in uptake, processing and presen-
tation of these tumor particles. Consequently, an anti-
tumor immunization against Her2/neu and other
unknown tumor-associated antigens is induced resulting
in the generation of cytotoxic T-cells and tumor-specific
antibody producing plasma cells. Finally, the mode of ac-
tion of triomab® antibodies, e.g. ertumaxomab, develops
a protective longterm anti-tumor immunity [9, 13, 14].
This effective attack of various immunologic cells acti-
vating complex immunologic mechanisms leads to signifi-
cant tumor cell elimination. Heiss et al. demonstrated that
patients with malignant ascites gain a clear clinical benefit
when treated i.p. with the trifunctional anti-EpCAM x
anti-CD3 antibody catumaxomab [15].
Recently, Kiewe et al. published promising data for the
trifunctional anti-Her2/neu x anti-CD3 antibody ertumax-
omab. In a phase I trial patients with metastatic breast
cancer were enrolled and treated with the trifunctional
antibody in a dose escalating scheme. A clinical response
to ertumaxomab treatment was seen in five out of fifteen
patients [12]. These results are encouraging and indicate
antitumor efficacy. Also, the finding that ertumaxomab
has a different mode of action compared with trastuzu-
mab, a monoclonal anti-Her2/neu antibody [16], strength-
ened the idea of investigating this triomab® antibody in a
second phase I study enrolling patients with Her2/neu
(IHC 1+/ISH positive, 2+, 3+) expressing solid tumors.
Fig. 1 Mode of action of a triomab antibody. The trifunctional antibody unites tumor cell, T cell and accessory cells to form a tri-cell complex to induce
tumor cell destruction and phagocytosis. Abbreviations: ADCC, antibody dependent cellular cytotoxicity; DC, dendritic cell; DC-CK1, dendritic cell cytokine
1; IL, interleukin; LFA, leukocyte function associated antigen; NK, natural killer cell; TNF-α, tumor necrosis factor alpha; INF-γ, interferon gamma; GM-CSF,
granulocyte macrophage colony-stimulating factor. Modified10,12
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A phase I trial was designed to investigate the safety,
tolerability and preliminary efficacy of ertumaxomab in
patients with solid tumors progressing after standard
therapy. In order to increase the amount of applied
doses and to reduce toxicity compared to a previous
study in breast cancer [12], we used a modified dosing
schedule with small dose escalation steps and five con-
secutive, weekly administrations.
Methods
Study design
The primary objective in this single center phase I trial
was the evaluation of safety and tolerability of the tri-
functional antibody ertumaxomab in patients with Her2/
neu expressing solid tumors in order to determine the
maximum tolerated dose (MTD) and to establish a rec-
ommended dose (RD) for further investigations. Second-
ary endpoints were antitumor activity (disease control
rate) and the measurement of immunological response
(anti-drug antibodies [HAMA], humoral immune re-
sponses [Anti-EpCam- and anti-Her2/neu antibodies],
lymphocyte cell count).
The study (EudraCT number: 2011-003201-14; Clinical-
Trials.gov identifier: NCT01569412) was conducted ac-
cording to the principles of the International Conference
of Harmonization-Good Clinical Practice and approved by
the institutional ethics committee. All relevant authorities
were notified according to German drug law.
Patient eligibility
Patients were eligible if they had histologically confirmed
solid Her2/neu positive (1+/ISH positive, 2+ and 3+) tu-
mors, no available standard treatment, measurable dis-
ease according to RECIST 1.1., disease progression
during or after standard therapy, age >18 years, ECOG
performance status 0–2, adequate hematological, liver,
kidney and cardiac function (LVEF >50 %). Unlike com-
mon criteria for anti-Her2/neu strategies, patients with
score 2+ were eligible regardless of their ISH results, as
“immunotherapy effects” were expected also in patients
with moderate Her2/neu overexpression.
Patients were excluded if they had known hypersensi-
tivity to murine proteins or other components of the
drug, any concurrent chemotherapy, radiotherapy, hor-
mone therapy, immunotherapy or treatment with any in-
vestigational drug within 2 weeks prior to study entry, a
documented autoimmune disease, HIV, HBV, HCV,
acute or chronic infections or other concurrent non-
malignant co-morbidities, ≥5 preceding chemotherapy
lines (to exclude potentially immunocompromised pa-
tients), prior diagnosis of any other uncured malignancy,
any documented evidence of symptomatic brain or cen-
tral nervous system metastases or abnormal organ or
bone marrow function.
All patients signed an informed consent form before
participating in the trial.
Treatment plan and dose escalation
In this investigator driven, open label, uncontrolled trial
the administration of ertumaxomab followed a predefined
dose escalation scheme (Table 1) consisting of two dose-
identical cycles with five ascending doses (10 μg to
500 μg) per cycle. In order to avoid cytokine release re-
lated symptoms associated with application of higher
doses in treatment naïve patients, an intraindividual dose
escalating schedule in each cohort was chosen, starting
with low doses. Patients were treated once weekly from
day 1 to 28 (i.e. one cycle) followed by a treatment-free
interval of 21 days in-between (Fig. 2). The dose escalation
into the next dose level occurred when three patients had
received all five administrations of the first cycle without
experiencing a dose limiting toxicity (DLT). If one patient
had shown a DLT, additional three patients had to be en-
rolled and treated at the same dose level before proceed-
ing into next dose level. If a DLT was seen in two patients
at a given dose level, the MTD had been exceeded. Dose
levels 1, 5, 9 and 13 were the main cohorts (in bold let-
ters). The intermediate cohorts served to identify the
MTD if ≥ 2 DLTs occurred in a main cohort (Table 1).
Drug administration
Ertumaxomab was manufactured by TRION Pharma
GmbH, Munich, under good manufacturing practice
conditions and approved by the local authority. The
Table 1 Dose escalation scheme
Dose level Escalation scheme [μg] No. of pts
1a 10-50-100-100-100 3–6
2 10-50-100-100-150 3–6
3 10-50-100-150-150 3–6
4 20-50-100-150-150 3–6
5a 20-50-100-150-200 3–6
6 20-50-100-150-250 3–6
7 20-50-100-200-200 3–6
8 50-100-150-200-200 3–6
9a 20-50-100-200-300 3–6
10 20-50-100-200-350 3–6
11 50-100-100-150-200 3–6
12 50-100-150-200-200 3–6
13a 50-100-150-200-300 3–6
14 50-100-150-300-300 3–6
15 50-150-150-300-300 3–6
16 50-150-300-400-500 3–6
Abbreviations: Pts patients
aMain cohort
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antibody was supplied by TRION Pharma as a sterile,
clear, colorless, preservative-free concentrate in prefilled
syringes. The syringes contained 10 μg or 50 μg of anti-
body and had to be dissolved in 0.9 % sodium chloride
solution to a total volume of 10 ml or 50 ml. Ertumaxo-
mab was administered as an i.v. infusion with a constant
rate over 3 h. Afterwards, 600 mg of Ibuprofen were
given orally to allay possible side effects of the immuno-
logic therapy. Patients remained under hospital care and
surveillance for 24 h after start of the infusion.
Toxicity assessment
Adverse Events (AE) were assessed at every visit by clinical
examination and laboratory tests and graded according to
the National Cancer Institute Common Toxicity Criteria
(CTC), version 4.0. Respectively, patients were monitored
frequently during their stay at the hospital and at the
scheduled follow-up visits: medical examinations includ-
ing vital signs, general physical examinations, electrocardi-
ography and echocardiography were performed for safety
before or during drug administration. Laboratory safety
parameters including blood chemistry and hematology
were measured before and 24 h after every infusion.
DLTs were predefined in the study protocol as any
grade ≥3 drug related non-hematological toxicity except
events that were not optimally treated with standard
medication >3 days of duration, any irreversible grade
≥3 infusion-related reaction (defined as allergic reaction,
fever, pain, bronchospasm, wheezing or hypoxia, occur-
ring during or within 24 h after completing an infusion
and resolving with a reduced infusion rate, supportive
care and/or the administration of corticosteroids); any
grade ≥3 elevation of liver enzymes that was not declin-
ing within 7 days after drug administration; any grade ≥4
toxicity, which have not been mentioned above as well
as any grade ≥3 event considered to be a DLT by the in-
vestigator. Moreover, fatigue (CTC grade ≥3) lasting less
than 14 days and isolated laboratory abnormalities grade
≥3 that resolved to baseline or CTC grade 2 within
7 days without clinical sequelae or need for therapeutic
intervention were not considered as a DLT.
Efficacy measurement
Tumor assessments according to response evaluation
criteria in solid tumors (RECIST) were planned for the
screening, the treatment-free interval before the second
cycle (day 42–49) and for the end of study (day 108) as
well as for follow up visits.
Immunological analyses
As ertumaxomab is an antibody derived from mouse and
rat IgG, it has the potential of immunogenicity when ad-
ministered to humans. Thus, patient plasma samples for
the determination of human anti-murine antibodies
(HAMAs) were collected before the first cycle, before the
second cycle and at the end of study. Testing for HAMAs
was performed using the Medac test (Medac, Hamburg).
Also, humoral immune responses against tumor-
associated antigens e.g. anti-EpCam- and anti-Her2/neu
antibodies were measured during the treatment. For the
detection of anti-EpCam antibodies, a bridging ELISA
format was applied, anti-Her2 antibodies were mea-
sured by immobilization of recombinant Her2 (Bender
Med Systems) to the plate surface and using Hercep-
tin as a calibrator. These assays provided information
about potential vaccination effects against various
tumor-associated antigens evolving during ertumaxo-
mab treatment.
Lymphocyte subsets were analyzed from peripheral
blood samples obtained before each infusion and
24 h after each infusion. Percentage and absolute
counts of the different lymphocyte populations were
determined using the Becton Dickinson (BD) Multit-
est IMK kit.
Statistics
This study was exploratory and not powered to address
any pre-defined hypotheses. The safety and efficacy ana-
lysis was performed on every patient who received at
least one infusion of ertumaxomab. Also, safety and effi-
cacy were analyzed by appropriate descriptive statistics.
All other endpoints were summarized descriptively.
Fig. 2 Study design. Abbreviations: CT, computed tomography; PD, progressive disease; EoS, End of Study; FUP, follow up
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Results
Patient characteristics
Out of 14 enrolled patients, three patients received only
two administrations of the investigational antibody ertu-
maxomab and had to be replaced. Reasons for discon-
tinuing the trial were allergic reaction, death and liver
failure all classified as non DLT (e.g. disease related).
Therefore, eleven patients were treated with ertumaxo-
mab according to protocol. They all completed the first
cycle, three of them continued with the second cycle.
The patient characteristics are outlined in detail in
Table 2.
Dose escalation
Fourteen patients were enrolled in four main cohorts with
different dose levels: cohort 1 (10-50-100-100-100 μg),
three patients; cohort 5 (20-50-100-150-200 μg), four pa-
tients; cohort 9 (20-50-100-200-300 μg), three patients;
cohort 13 (50-100-150-200-300 μg); four patients. In this
dose escalation scheme, single doses up to 300 μg were
well tolerated. The received doses ranged from 10 μg to
300 μg as a single application and from 360 μg to 800 μg
in total per cycle. The dose escalation proceeded into the
13th dose level (50-100-150-200-300 μg) without showing
a DLT. Consequently, in this scheme the MTD is not
reached and a RD not found so far.
Safety
Out of all serious adverse events (SAEs) that occurred
during the trial (n = 12), only two were possibly or cer-
tainly related to the administration of the investigated
antibody ertumaxomab and thus classified as SAR (ser-
ious adverse reaction): one patient (#5) experienced an
allergic reaction after the second application (50 μg).
Her main symptom was dyspnea with pain in the upper
abdomen. The other SAR emerged in patient #14 after
his second infusion with 100 μg of ertumaxomab. He de-
veloped a fever (CTC grade 1) which was accompanied
by other symptoms as chills, abdominal pain, nausea and
vomiting leading to unplanned hospitalization. Both
SARs were fully reversible.
All patients showed treatment-related toxicities. Most
frequent adverse events (AEs) were fatigue (14/14 pa-
tients, 100 %), (tumor-) pain (13/14 patients, 93 %),
cephalgia (12/14 patients, 86 %), chills (11/14 patients,
79 %), nausea (8/14 patients, 62 %), fever (7/14 patients,
50 %), emesis (7/14 patients, 50 %) and diarrhea (5/14
patients, 43 %). All AEs were mild and completely re-
versible. An infusion with paracetamol ended or eased
the symptoms during the ertumaxomab administration
immediately. There was no cardiotoxicity revealed by
monitoring of the clinical heart function during treat-
ment with ertumaxomab. All treatment-related adverse
events that occurred in the total population are listed in
detail in Table 3.
Efficacy
Three out of eleven patients evaluable for response
showed disease stabilization or partial response after the
first cycle of ertumaxomab (day 42–49): A partial re-
sponse was seen in patient #6 (metastatic breast cancer)
with a regression of hepatic metastases at first tumor
evaluation. At the end of study, a progression in her axil-
lary and hilar lymph nodes could be observed, but liver
metastases were still in regress. Two patients (#1- rectal
cancer and #2-head and neck cancer) were stable after
the first cycle of ertumaxomab. They also had a progres-
sive disease at end of study. There was no difference be-
tween tumor assessments according to RECIST. All
three patients had Her2 IHC score 3+ tumors, two pa-
tients with disease stabilization were treated in dose level
1, one patient with partial response in dose level 5. Se-
lected characteristics of disease together with an overall
response of all patients treated with ertumaxomab are
provided in Table 4.
Table 2 Patient characteristics
Patient characteristics No. of patients (%)
n = 14
Sex
Male
Female
4 (28.6)
10 (71.4)
Age
Median age, years (range) 54,5 (35–72)
ECOG performance status
O
1
2
8 (57.1)
5 (35.7)
1 (7.1)
Primary tumor location
Breast
Rectum
Stomach
Othersa
5 (35.7)
3 (21.4)
3 (21.4)
3 (21.4)
No. of organs involved (primary excluded)
1
2
3
≥4
5 (35.7)
3 (21.4)
2 (14.3)
4 (28.6)
Organs involved (primary tumor excluded)
Lymph nodes
Lung
Liver
Abdominal Wall
Bone
Othersb
7 (50.0)
5 (35.7)
3 (21.4)
3 (21.4)
3 (21.4)
10 (71.4)
Her2 status
IHC 2+/ISH+
IHC 3+
3 (21.4)
11 (78.6)
Abbreviations: ECOG Eastern Cooperative Oncology Group, IHC
immunohistochemistry, ISH in-situ hybridisation
aOthers: head and neck (2 pts), pancreas (1 pt)
bOthers: adrenal gland, spleen, bladder, lymphangiosis carcinomatosa, pleura,
peritoneum, chest wall, brain, skin
Haense et al. BMC Cancer  (2016) 16:420 Page 5 of 10
Immunologic parameters
All patients showed a decrease of their CD3+ T cell
count 24 h after receiving the investigational drug. One
week later, their CD3+ lymphocyte count had normal-
ized to baseline values. The decrease was dose
dependent. Thus, the transient lymphocytopenia was
more pronounced in higher levels of dose. The median
distribution of the CD3+ T cell count of all patients is
plotted in Fig. 3.
One out of five evaluable patients evolved anti-
EpCam antibodies during the trial. The other four of
these five patients had already preexistent anti-EpCam
antibodies. The levels were in the range of 219–
546 ng/ml and did not change significantly during
treatment. Also, at end of study, anti-Her/neu anti-
bodies were found in three out of five patients, all
without pre-existing anti Her2/neu antibodies. Figure 4
shows a representative of a typical humoral immune
response with corresponding, increasing levels for anti
Her2/neu and anti-EpCam antibodies, which was seen
in patient #4.
The analysis for HAMAs at screening showed that all
tested patients were negative for HAMAs, whereas eight
out of nine evaluable patients were found to be HAMA-
positive at the end of study. There was no dose depend-
ency seen for the development of HAMAs neither was a
correlation to a different toxicity profile detected.
Discussion
In this phase I trial we could show that treatment
with ertumaxomab in a slow weekly escalating dosing
regimen for five consecutive applications is feasible.
Table 3 Adverse events (AEs) with possible relationship to ertumaxomab treatment (Adverse Drug Reaction) graded according to
CTC AE (version 4.0)
Dose level 1 Dose level 5 Dose level 9 Dose level 13 Ʃ
AEs
(n = 3) (n = 4) (n = 3) (n = 4) (n = 14)
n n n n n [%]
AEs G1/G2 G3 G1/G2 G3 G1/G2 G3 G1/G2 G3 Ʃ
Fatigue 2 1 1 3 2 1 3 1 14 (100,0)
Cephalgia 2 - 3 - 3 - 4 - 12 (85,7)
Chills 3 - 2 - 3 - 3 - 11 (78,6)
Nausea 1 - 2 - 2 - 3 - 8 (61,5)
Emesis 1 - 2 - 2 - 2 - 7 (50,0)
Fever 1 - 2 1 2 - 1 1 7 (50,0)
Hypertension 3 - 2 - 1 - 1 - 7 (50,0)
Tumorpain - - 1 2 2 - 1 1 7 (50,0)
Paina 1 - 4 - 1 - - - 6 (42,9)
Diarrhea 1 - 2 - 1 - 1 - 5 (42,9)
Pain in the limbs - - 2 - - - 3 - 5 (42,9)
↑CRP 1 - 1 - 1 - 1 - 4 (28,6)
Tachycardia 1 - 1 - 2 - - - 4 (28,6)
↑GGT - - 2 - 1 - - - 3 (21,4)
↑ALT/AST - - 1 - 1 - - - 2 (14,3)
↓Lymphocytes - - 2 - - - - - 2 (14,3)
Agitation - - 1 - - - 1 - 2 (14,3)
Dermatitis - - 2 - - - - - 2 (14,3)
Hypotension 1 - - - 1 - - - 2 (14,3)
Dizziness - - - - 1 - 1 - 2 (14,3)
Sensorium - - 2 - - - - - 2 (14,3
Allergic reactionb - - 1 - - - - - 1 (7,1)
Per patient every AE was counted once with its highest CTC grade. Only AE occurring in > 1 pt are listed (exception: allergic reaction)
Abbreviations: G grade according to CTC criteria, CRP C-reactive protein, ALT/AST aspartate aminotransferase/alanine aminotransferase, GGT
gamma-glutamyl transpeptidase
aPain: not further specified
bSymptoms: Sensorium, edema, tachypnea, cold hands, CRP elevation
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The toxicity with this particular dosing schema is fa-
vorable. We observed no grade 4 toxicities and an ac-
ceptable incidence of grade 3 toxicities (fatigue in six,
fever in two, and pain in three of 14 patients). Three
patients had to be replaced as they received only two
applications. Two of them had rapid tumor progres-
sion leading to cancer related death or liver failure.
This relatively high replacement rate was mostly at-
tributable to tolerant patient selection criteria as
ECOG 2 patients were allowed to be enrolled. In
comparison to published results from the previous
phase I study with ertumaxomab in metastatic breast
cancer [12], our study was associated with less acute
toxicities, e.g. fever (all grades 50 % vs. 94 %). Fur-
thermore, we did not observe any grade 4 ALT/AST
(0 % vs. 42 %). These differences are most likely
attributable to the different dosing and escalating
schema. The study by Kiewe reported more cytokine
release related symptoms, especially at the second
and third application of the drug, which is related to
the rapid escalation of the antibody dose. This issue is
also reflected in the MTD achieved in the mentioned
study, which was at 100 μg per single dose (in a 10-100-
100 μg dosing schedule). In our study no DLT was ob-
served in the main dosing cohorts and an MTD was not
achieved. The results confirm the tolerability of the new
schedule that allows the administrations of higher doses
of the antibody. We planned to amend the protocol and
further escalate the dose, when the trial withhold due to
the unavailability of the study drug. Regarding the im-
mune response to ertumaxomab, we made following ob-
servations: CD3+ T cell counts decreased 24 h post
Table 4 Corresponding study data and clinical charcteristics of patients
No. Age range Tumor ECOG PS No. of prior CHT Organs involved Her2 Status1 Dose level No. of cycles Best response
01 70–80 Rectum 1 4 LN, PUL, HEP, ADR IHC 3+ 1 2 SD
02 70–80 Head and neck 1 3 LN, PUL IHC 3+ 1 2 SD
03 40–50 Rectum 0 3 LN, SPLEEN, BLADDER,
ABDOM WALL
IHC 3+ 1 1 PD
04 60–70 Pancreas 1 3 ABDOM WALL IHC 2+, ISH + 5 1 PD
05 50–60 Breast 0 4 PUL, OSS, LYMPHANG IHC 3+ 5 0 ND
06 50–60 Breast 0 3 HEP IHC 3+ 5 2 PR
07 50–60 Rectum 1 3 LN, PUL, PLEU,
ABDOM WALL, PERI
IHC 2+, ISH+ 5 1 PD
08 40–50 Stomach 0 4 LN IHC 3+ 9 1 PD
09 50–60 Breast 0 3 CHEST WALL,
CEREB, HEP, OSS
IHC 3+ 9 1 PD
10 50–60 Breast 0 4 LN, CUT IHC 3+ 9 1 PD
11 60–70 Head and neck 1 4 PUL, PLEU, OS IHC 3+ 13 1 PD
12 50–60 Stomach 0 4 PERI, OVAR IHC 3+ 13 1 PD
13 30–40 Breast 0 4 CUT IHC 3+ 13 1 PD
14 50–60 Stomach 1 1 LN IHC 2+ 13 1 PD
Fig. 3 Median distribution of CD3+ T cells of all patients. Abbreviations: CD, Cluster of differentiation; appl, application
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infusion, but normal values were obtained 1 week later.
Transient lymphocytopenia was also observed in other
clinical studies with trifunctional antibodies [12, 15] and is
provoked by their mode of action: The full reversibility
and the short recovery period indicate that the
phenomenon is attributed to lymphocyte redistribution
which could be confirmed in a pre-clinical model [17].
In contrast to the previous published study [12] of
ertumaxomab with low incidence of HAMA (25 %)
and HARA (31 %), we found HAMA development in
eight of nine evaluable patients (89 %) in our study.
Most probably, this may be referred to the prolonged
dosing schedule used consisting of two cycles with
each five applications. However, the induction of
HAMA was not dose dependent, nor a correlation
with a different toxicity profile was observed. In gen-
eral, the development of HAMA was not of clinical
and practical issue, indicating that a second treatment
cycle could be safely administered. Remarkable in this
context are results from a phase II/III study with the
trifunctional antibody catumaxomab demonstrating a
prolonged survival in HAMA positive compared to
HAMA negative patients [18].
The monitoring of humoral responses to EpCAM
and Her2/neu (in patients without pre-existing
humoral immunity) showed increasing antibody titers
during treatment in three of five evaluable patients,
particular in one patient with corresponding increase
in anti-EpCAM and anti-Her2/neu antibodies. Espe-
cially the observation of a humoral anti-EpCAM re-
sponse confirms the potential of the trifunctional
antibody to induce a polyclonal anti-tumor response
against tumor-associated antigens which are not tar-
geted by the trifunctional antibody itself. Similar
immunological activity with increasing humoral and
cellular immunity against different tumor-associated
antigens was observed with the EpCAM-specific tri-
functional antibody catumaxomab applied to gastric
cancer patients in the adjuvant setting [19]. These re-
sults serve as a further indicator and proof of concept
for the “trifunctionality” of ertumaxomab in vivo
(with an involvement of antigen presenting cells),
leading to immune recognition and priming of a poly-
clonal humoral immune response against tumor-
associated antigens. However, due to the low evalu-
able patient numbers any conclusion between the in-
duction of humoral immunity and clinical efficacy
cannot be drawn.
Regarding the clinical efficacy, we observed two dis-
ease stabilizations (one patient with rectal cancer and
one with head and neck cancer) and one partial re-
mission (breast cancer) in 11 patients completing
1 cycle and being evaluable for response. The study
was designed as a dose finding study. All patients
were heavily pretreated, so responses are rarely ex-
pected in this patient group.
Although it is known that Her2 positive breast cancer
benefits most from anti-Her2 strategies, our results sup-
port the evaluation of ertumaxomab in other Her2 posi-
tive malignancies as well.
Up to now, several anti Her2/neu strategies are
adopted in breast cancer, the prototype disease for
Her2/neu targeted therapy. The most known and
most widely used is trastuzumab, a recombinant hu-
manized monoclonal antibody against Her2/neu. Fur-
ther approved drugs are lapatinib, a dual tyrosine
kinase inhibitor of Her1 (also known as EGFR) and
Her2/neu, trastuzumab-emtansine, an antibody-drug
Fig. 4 Humoral immune response against tumor-associated antigens (EpCam and Her2/neu) found in patient #4. Abbreviations: Appl, application
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conjugate, consisting of trastuzumab and the cytotoxic
agent mertansine (DM1), and pertuzumab, a Her2/
neu dimerization inhibitor. The antibody based strat-
egies are supposed to be functioning not only by
blocking the signal transduction but also by an add-
itional immunologic effect. Despite positive results
from different phase I studies dealing with anti Her2/
neu vaccination strategies, this concept of potential
long lasting tumor control or even a disease eradica-
tion could not be established yet [20]. With the novel
approach using the trifunctional antibody ertumaxo-
mab different disadvantages and obstacles known
from the classical vaccination concept could be over-
come, like limitation of immune response to one or
few epitopes, HLA restriction, or activation of only
one pathway of immune response. Ertumaxomab is
supposed to be acting by direct tumor cell/effector
interaction and an indirect way by establishing a long
lasting immune response.
Taken together, the results of our study have several
implications:
First, we could show, that the dosing protocol consist-
ing of two cycles with each five consecutive applications
of ertumaxomab (50-100-150-200-300 μg) was feasible
and tolerable. A further dose escalation to higher dose
levels, as planned, is currently not possible as the com-
pany has to produce a new batch of the investigational
drug. It has to be noted, that we could not yet define a
MTD with our dosing schema.
Second, in diseases with approved anti Her2/neu drug
therapies (breast cancer, gastric cancer), ertumaxomab
could expand the therapeutic spectrum, either in (anti
Her2) resistant/refractory disease or additionally to estab-
lished anti Her2 strategies, or even adjuvant concepts.
Third, in Her2/neu overexpressing solid tumors, other
than breast and gastric cancer, it could be evaluated as a
new personalized treatment approach beyond standard
therapy.
In conclusion, the results of our study together with
previously published data warrant further evaluation of
ertumaxomab in Her2/neu overexpressing solid tumors
as a new targeted therapy adding to the armamentarium
of personalized cancer treatment.
Conclusion
In this study we could show that treatment with ertu-
maxomab in a slow weekly escalating dosing regimen for
five consecutive applications (50-100-150-200-300 μg) is
feasible and could confirm the tolerability of the new
schedule that allows the administrations of higher doses
of the antibody. The results of our study together with
previously published data warrant further evaluation of
ertumaxomab in Her2/neu overexpressing solid tumors.
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